A study of 193,260 individuals found overlapping tick-borne antibody levels more frequently among those with Lyme antibodies, highlighting diagnostic challenges when active coinfections are not confirmed.
News|Videos|September 30, 2025
Current Classes and Manufacturer Guidelines for Medical Devices
Understand who the key organizations are when it comes to the cleaning and disinfection of non-critical medical devices.
Advertisement
Medical devices fall under three classes depending on the risk they pose to patients. The classes include potential risk: high, potential risk: medium, and potential risk: low. This segment explains the differences between each class and what requirements are expected of each by the FDA.
Advertisement
Related to this article
A shifting mask or fogged eyewear can interrupt focus when precision matters most. Dana Weaver Storm, MHA, BSN, RN, examines the challenges of prolonged surgical mask use and how perioperative leaders can support comfort, visibility, and consistent adherence.
What happens when one disinfectant cannot satisfy every IFU? At AHE in New Orleans, Diane Cullen discusses weighted risk assessment, documenting difficult decisions, and why infection prevention and EVS need to work together.
Turnover pressure can leave critical OR cleaning steps unfinished. Karen deKay, MSN, RN, EBP-C, CNOR, CIC, FAPIC, examines common gaps in environmental hygiene and how shared responsibilities, attention to disinfectant contact time, and ongoing education can help teams strengthen practices between cases.
A patient with fever and no recent travel could still have dengue. Florida’s local transmission highlights why clinicians and infection preventionists should look beyond travel history and recognize warning signs.
High contact follow-up rates suggest progress, but who is being missed? Inside the DRC’s Ebola response, shortages, strained treatment centers, and gaps in community trust reveal a more complicated story.
Sterile processing professionals face constant interruptions, cognitive overload, increasingly complex devices, and hundreds of IFUs. Randalyn Harreld, CRCST, FHSPA, explains why health care organizations must address the human factors behind SPD performance rather than expecting frontline professionals to simply absorb ever-increasing complexity.
Long-acting HIV therapies promise greater convenience, but fewer doses alone may not solve adherence or access challenges. Lloyd Bibby and Pooja Goyal, MS(Pharm), discuss patient choice, weekly oral and injectable therapies, health system capacity, equitable access, and the real-world measures that will define success.
Advertisement
Advertisement